Loading...

Notable Labs, Ltd.

NTBL•NASDAQ
Healthcare
Biotechnology
$0.25
$-0.09(-27.68%)

Notable Labs, Ltd. (NTBL) Stock Overview

Explore Notable Labs, Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.6/100

Key Financials

Market Cap2.4M
P/E Ratio-0.26
EPS (TTM)$-1.09
ROE-0.96%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.07

NTBL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Notable Labs, Ltd. (NTBL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.07.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.26 and a market capitalization of 2.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NTBLStats details for NTBL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NTBLAnalyst Recommendations details for NTBL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

CEO

Kaile Zagger

Employees

16

Headquarters

320 Hatch Drive, Foster City, CA

Founded

2014

Frequently Asked Questions

;